Sign In
Buy VCYT
$46.32
-13.46 (-22.52%)
At Close: Jul 31, 2026
Here's Why Veracyte (VCYT) is a Strong Growth Stock
10:45am, Monday, 14'th Apr 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Veracyte (VCYT) Just Overtook the 20-Day Moving Average
10:35am, Thursday, 10'th Apr 2025
After reaching an important support level, Veracyte (VCYT) could be a good stock pick from a technical perspective. VCYT surpassed resistance at the 20-day moving average, suggesting a short-term bull
Strength Seen in Veracyte (VCYT): Can Its 13.0% Jump Turn into More Strength?
10:05am, Thursday, 10'th Apr 2025
Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Veracyte (VCYT) Up 0.7% Since Last Earnings Report: Can It Continue?
12:30pm, Wednesday, 26'th Mar 2025
Veracyte (VCYT) reported earnings 30 days ago. What's next for the stock?
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 35.05%: Here's is How to Trade
10:55am, Wednesday, 26'th Mar 2025
The mean of analysts' price targets for Veracyte (VCYT) points to a 35.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer
04:05pm, Tuesday, 25'th Mar 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Data Demonstrate Accuracy of Veracyte's Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces 8 Abstracts Highlighting Performance and Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25.
Veracyte Stock Surges 45.6% in a Year: What's Driving the Rally?
09:45am, Thursday, 13'th Mar 2025
Strength in VCYT's Afirma and Decipher tests continues to draw investors' attention.
Top 3 Medical Instruments Industry Stocks to Ride the GenAI Boom
12:50pm, Thursday, 27'th Feb 2025
FMS, MASI and VCYT from the Zacks Medical Instruments industry are worth buying based on genAI adoption, strategic developments and strong fundamentals. Yet, geopolitical complications and wage and su
Solid Growth, Soft Outlook: Why I'm Holding On Veracyte
10:32am, Tuesday, 25'th Feb 2025
Veracyte, Inc. shows strong revenue growth and market share in genomic diagnostics, particularly with its Decipher and Afirma tests, but faces significant near-term challenges. 2024 ended positively w
Veracyte Stock Falls Despite Q4 Earnings and Revenue Beat
09:00am, Tuesday, 25'th Feb 2025
VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests.
Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript
10:53pm, Monday, 24'th Feb 2025
Veracyte, Inc. (NASDAQ:VCYT ) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Shayla Gorman - Senior Director of Investor Relations Marc Stapley - Chief Executive Of
Veracyte (VCYT) Q4 Earnings and Revenues Beat Estimates
06:30pm, Monday, 24'th Feb 2025
Veracyte (VCYT) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to loss of $0.04 per share a year ago.
Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results
04:05pm, Monday, 24'th Feb 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the fourth quarter and full year ended December 31, 2024. “I'm incredibly proud of w
Is Veracyte Stock a Good Addition to Your Portfolio Right Now?
09:25am, Friday, 21'st Feb 2025
VCYT stays on investors radar due to the strong performance of the Afirma and Decipher franchises.
